Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. develops digital health and digital therapeutics solutions for people managing chronic conditions. The company’s multi-condition platform uses data analytics, connected health devices, personalized interventions and one-on-one coaching across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
DRIO news commonly covers quarterly financial results, conference calls, commercial activity with health plans, payers, self-insured employers, care providers and consumers, and clinical research based on real-world platform data. Other recurring updates include AI-enabled product development such as DarioIQ, evidence publications, board and governance changes, and capital or credit arrangements supporting the company’s digital health business.
DarioHealth (NASDAQ: DRIO) has announced a strategic commercial agreement with GreenKey Health to address the $150 billion sleep apnea market. The collaboration combines Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach to obstructive sleep apnea (OSA) management.
The partnership targets 29 million Americans affected by sleep apnea, with up to 80% of moderate to severe cases currently undiagnosed. The joint solution aims to improve member outcomes, reduce healthcare costs, and increase productivity through integrated behavioral health, sleep, and cardiometabolic care. The initiative will focus on engaging Commercial, ASO, Medicaid, Medicare Advantage plans, self-funded employers, and other healthcare stakeholders.
DarioHealth (NASDAQ: DRIO) presented four groundbreaking studies at the 85th Annual American Diabetes Association Scientific Sessions, showcasing significant achievements in GLP-1 medication management and AI-powered personalization.
A landmark study of 715 GLP-1 users demonstrated remarkable improvements, with average blood glucose dropping from eA1c of 9.0% to 6.7%. Notably, patients maintained stable outcomes for six months after discontinuing GLP-1 medication, showing no significant weight or glucose rebound.
The company's AI research achieved 89% accuracy in predicting next-month blood glucose levels using machine learning models. The studies revealed that the first four months of engagement are crucial for personalized care, with older adults (60+) showing stronger sustained outcomes.
DarioHealth (NASDAQ: DRIO) has published new research in the Journal of Medical Internet Research demonstrating the effectiveness of their personalized digital health interventions for increasing flu vaccination awareness among diabetes patients. The study analyzed 64,904 members divided into three groups: one receiving monthly flu vaccination messages, another receiving more personalized and frequent messages, and a control group.
The research revealed that the group receiving personalized messaging showed significantly higher awareness of flu-related risks and increased vaccination rates compared to the group receiving standard messages. This pragmatic follow-up study built upon a previous randomized controlled trial, translating initial insights into real-world applications through Dario's diabetes management platform.
DarioHealth (Nasdaq: DRIO), a leader in the global digital health market, has announced it will release its Q1 2025 financial results on Wednesday, May 14th, 2025, before market opens. The company will host a conference call and webcast at 8:30 a.m. Eastern Time, featuring CEO Erez Raphael and CCO Steven Nelson.
Participants can join via dial-in numbers (1-800-717-1738 domestic or 1-646-307-1865 international), through the Call me™ link, or via webcast. A replay will be available until May 28th, 2025, using passcode 1118523.
DarioHealth (NASDAQ: DRIO) has secured a strategic debt refinancing facility of up to $50 million from Rand Capital and Callodine Group. The company received $32.5 million at closing, with potential access to an additional $17.5 million based on achieving certain revenue thresholds. The five-year credit agreement matures in April 2030 and includes the issuance of warrants to purchase 2,114,140 shares at $0.8278 per share. Notably, the refinancing defers debt amortization from end of 2025 to 2028, providing DarioHealth with enhanced operational flexibility to execute its B2B2C strategy across pharmaceutical companies, self-insured employers, and payer channels.
DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.
Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.
Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.
DarioHealth (Nasdaq: DRIO) has announced a strategic partnership with a leading national benefit administrator to provide its cardiometabolic solution, including a GLP-1 support program and AI-driven digital health suite to employers. The partnership, which began contributing to revenue in January 2025, addresses rising healthcare costs associated with metabolic conditions.
The collaboration targets the GLP-1 market, projected to reach $100 billion by 2030, and the cardiometabolic disease market, expected to exceed $1.2 trillion by 2033. Dario's comprehensive approach addresses the challenge of GLP-1 medication discontinuation through personalized coaching, AI-driven monitoring, and behavior change strategies.
This partnership marks Dario's first national benefit administrator collaboration, enabling faster employer onboarding and immediate impact on B2B2C recurring revenues for 2025. The agreement serves as a foundational entry into a priority growth segment and provides a reference model for expansion across other national administrators and payer channels.
DarioHealth (NASDAQ: DRIO) has secured a partnership with a major U.S. healthcare research and medical institution, marking its second significant healthcare employer agreement. The partnership, which is already generating recurring revenue in 2025, involves the implementation of Dario's complete suite of AI-powered digital health solutions.
The institution will deploy Dario Health, Dario Mind, and Dario Move platforms, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company's solutions have demonstrated above-average engagement rates and significant improvements in health metrics, including reductions in A1c, blood pressure, and MSK-related pain.
DarioHealth (DRIO) reported strong financial results for Q4 and full-year 2024, with annual revenue increasing 32.9% to $27.0 million. The company's B2B2C channel showed remarkable growth, with recurring revenues rising 300% year-over-year. Q4 2024 revenue reached $7.6 million, up 110% from Q4 2023.
Key highlights include completion of a $25.6 million equity financing, resulting in a $34.5 million proforma cash balance. Operating loss decreased by 35% to $11.7 million (GAAP) in Q4 2024. The company added 36 new employer and health plan clients in 2024, bringing total client base to 83, with a projected 50% net client growth in 2025.
Following the Twill acquisition, Dario expanded its AI-powered platform to support five chronic conditions. The company expects to achieve operational cash flow breakeven by end of 2025, supported by an anticipated 20% reduction in operating expenses. Gross margins exceeded 80% in the B2B2C business over the past three quarters.